Dimensional Fund Advisors LP lifted its holdings in shares of ChemoCentryx Inc (NASDAQ:CCXI) by 15.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 632,061 shares of the biopharmaceutical company’s stock after buying an additional 84,290 shares during the period. Dimensional Fund Advisors LP’s holdings in ChemoCentryx were worth $6,896,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also modified their holdings of the company. Metropolitan Life Insurance Co. NY boosted its position in shares of ChemoCentryx by 369.8% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 8,804 shares of the biopharmaceutical company’s stock worth $96,000 after buying an additional 6,930 shares during the period. Bank of New York Mellon Corp raised its holdings in ChemoCentryx by 6.8% during the third quarter. Bank of New York Mellon Corp now owns 126,848 shares of the biopharmaceutical company’s stock worth $1,604,000 after purchasing an additional 8,070 shares in the last quarter. Rhumbline Advisers raised its holdings in ChemoCentryx by 44.9% during the fourth quarter. Rhumbline Advisers now owns 30,596 shares of the biopharmaceutical company’s stock worth $334,000 after purchasing an additional 9,479 shares in the last quarter. Raymond James & Associates bought a new stake in ChemoCentryx during the fourth quarter worth approximately $133,000. Finally, BB&T Securities LLC raised its holdings in ChemoCentryx by 16.6% during the fourth quarter. BB&T Securities LLC now owns 114,827 shares of the biopharmaceutical company’s stock worth $1,252,000 after purchasing an additional 16,327 shares in the last quarter. Institutional investors and hedge funds own 58.14% of the company’s stock.
Several equities research analysts recently commented on CCXI shares. ValuEngine cut ChemoCentryx from a “strong-buy” rating to a “buy” rating in a report on Monday, May 20th. Zacks Investment Research raised ChemoCentryx from a “hold” rating to a “buy” rating and set a $13.00 target price on the stock in a report on Wednesday, May 15th. BidaskClub cut ChemoCentryx from a “buy” rating to a “hold” rating in a report on Wednesday. Raymond James dropped their target price on ChemoCentryx from $24.00 to $17.00 and set a “strong-buy” rating on the stock in a report on Thursday, June 6th. Finally, B. Riley raised ChemoCentryx from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $12.50 to $22.00 in a report on Wednesday, March 27th. Four research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. ChemoCentryx has a consensus rating of “Buy” and an average target price of $17.71.
In other ChemoCentryx news, SVP Rajinder Singh sold 33,000 shares of the company’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $12.96, for a total value of $427,680.00. Following the transaction, the senior vice president now owns 43,614 shares of the company’s stock, valued at $565,237.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Geoffrey M. Parker sold 12,815 shares of the company’s stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $12.00, for a total value of $153,780.00. Following the completion of the transaction, the director now directly owns 85,014 shares in the company, valued at approximately $1,020,168. The disclosure for this sale can be found here. Insiders sold 246,570 shares of company stock worth $3,313,980 in the last ninety days. 12.20% of the stock is owned by corporate insiders.
Shares of NASDAQ:CCXI opened at $8.34 on Friday. ChemoCentryx Inc has a 12 month low of $8.06 and a 12 month high of $14.98. The company has a current ratio of 3.43, a quick ratio of 3.43 and a debt-to-equity ratio of 0.24.
ChemoCentryx (NASDAQ:CCXI) last announced its earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.24) by $0.01. The firm had revenue of $8.33 million for the quarter, compared to analysts’ expectations of $11.37 million. ChemoCentryx had a negative return on equity of 111.15% and a negative net margin of 97.22%. On average, analysts expect that ChemoCentryx Inc will post -0.92 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://www.dispatchtribunal.com/2019/06/15/dimensional-fund-advisors-lp-has-6-90-million-stake-in-chemocentryx-inc-nasdaqccxi.html.
ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis.
Further Reading: Cost of Capital
Want to see what other hedge funds are holding CCXI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ChemoCentryx Inc (NASDAQ:CCXI).
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.